O	0	9	Targeting	Target	VBG	B-VP
O	10	13	PIM	PIM	NN	B-NP
O	14	21	kinases	kinase	NNS	I-NP
O	22	29	impairs	impair	VBZ	B-VP
O	30	38	survival	survival	NN	B-NP
O	39	41	of	of	IN	B-PP
B-Cell	42	55	hematopoietic	hematopoietic	JJ	B-NP
I-Cell	56	61	cells	cell	NNS	I-NP
O	62	73	transformed	transform	VBN	B-VP
O	74	76	by	by	IN	B-PP
O	77	83	kinase	kinase	NN	B-NP
O	84	93	inhibitor	inhibitor	NN	I-NP
O	93	94	-	-	HYPH	B-NP
O	94	103	sensitive	sensitive	JJ	I-NP
O	104	107	and	and	CC	I-NP
O	108	114	kinase	kinase	NN	I-NP
O	115	124	inhibitor	inhibitor	NN	I-NP
O	124	125	-	-	HYPH	B-NP
O	125	134	resistant	resistant	JJ	I-NP
O	135	140	forms	form	NNS	I-NP
O	141	143	of	of	IN	B-PP
O	144	147	Fms	Fm	NNS	B-NP
O	147	148	-	-	HYPH	B-NP
O	148	152	like	like	JJ	I-NP
O	153	161	tyrosine	tyrosine	NN	I-NP
O	162	168	kinase	kinase	NN	I-NP
O	169	170	3	3	CD	B-NP
O	171	174	and	and	CC	I-NP
O	175	178	BCR	BCR	NN	I-NP
O	178	179	/	/	SYM	B-NP
O	179	182	ABL	ABL	NN	I-NP
O	182	183	.	.	.	O

O	185	193	Previous	Previous	JJ	B-NP
O	194	201	studies	study	NNS	I-NP
O	202	206	have	have	VBP	B-VP
O	207	212	shown	show	VBN	I-VP
O	213	217	that	that	IN	B-SBAR
O	218	228	activation	activation	NN	B-NP
O	229	231	of	of	IN	B-PP
O	232	235	the	the	DT	B-NP
O	236	242	signal	signal	NN	I-NP
O	243	253	transducer	transducer	NN	I-NP
O	254	257	and	and	CC	I-NP
O	258	267	activator	activator	NN	I-NP
O	268	270	of	of	IN	B-PP
O	271	284	transcription	transcription	NN	B-NP
O	285	286	5	5	CD	I-NP
O	287	288	(	(	(	O
O	288	293	STAT5	STAT5	NN	B-NP
O	293	294	)	)	)	O
O	295	300	plays	play	VBZ	B-VP
O	301	303	an	an	DT	B-NP
O	304	313	essential	essential	JJ	I-NP
O	314	318	role	role	NN	I-NP
O	319	321	in	in	IN	B-PP
O	322	336	leukemogenesis	leukemogenesis	NN	B-NP
O	337	345	mediated	mediate	VBN	B-VP
O	346	353	through	through	IN	B-PP
O	354	366	constitutive	constitutive	JJ	B-NP
O	367	376	activated	activate	VBN	I-NP
O	377	384	protein	protein	NN	I-NP
O	385	393	tyrosine	tyrosine	NN	I-NP
O	394	401	kinases	kinase	NNS	I-NP
O	402	403	(	(	(	O
O	403	406	PTK	PTK	NN	B-NP
O	406	407	)	)	)	O
O	407	408	.	.	.	O

O	409	416	Because	Because	IN	B-SBAR
O	417	420	PIM	PIM	NN	B-NP
O	420	421	-	-	HYPH	B-NP
O	421	422	1	1	CD	I-NP
O	423	425	is	be	VBZ	B-VP
O	426	427	a	a	DT	B-NP
O	428	433	STAT5	STAT5	NN	I-NP
O	434	440	target	target	NN	I-NP
O	441	445	gene	gene	NN	I-NP
O	445	446	,	,	,	O
O	447	449	we	we	PRP	B-NP
O	450	458	analyzed	analyze	VBD	B-VP
O	459	462	the	the	DT	B-NP
O	463	467	role	role	NN	I-NP
O	468	470	of	of	IN	B-PP
O	471	474	the	the	DT	B-NP
O	475	481	family	family	NN	I-NP
O	482	484	of	of	IN	B-PP
O	485	488	PIM	PIM	NN	B-NP
O	489	495	serine	serine	NN	I-NP
O	495	496	/	/	SYM	B-VP
O	496	505	threonine	threonine	NN	B-NP
O	506	513	kinases	kinase	NNS	I-NP
O	514	515	(	(	(	O
O	515	518	PIM	PIM	NN	B-NP
O	518	519	-	-	HYPH	O
O	519	520	1	1	CD	B-NP
O	521	523	to	to	TO	B-PP
O	524	527	PIM	PIM	NN	B-NP
O	527	528	-	-	HYPH	I-NP
O	528	529	3	3	CD	I-NP
O	529	530	)	)	)	O
O	531	533	in	in	IN	B-PP
O	534	537	PTK	PTK	NN	B-NP
O	537	538	-	-	HYPH	B-NP
O	538	546	mediated	mediate	VBN	I-NP
O	547	561	transformation	transformation	NN	I-NP
O	562	564	of	of	IN	B-PP
B-Cell	565	578	hematopoietic	hematopoietic	JJ	B-NP
I-Cell	579	584	cells	cell	NNS	I-NP
O	584	585	.	.	.	O

B-Cell	586	588	Ba	Ba	NN	B-NP
I-Cell	588	589	/	/	SYM	I-NP
I-Cell	589	591	F3	F3	NN	I-NP
I-Cell	592	597	cells	cell	NNS	I-NP
O	598	609	transformed	transform	VBN	B-VP
O	610	612	to	to	TO	B-PP
O	613	619	growth	growth	NN	B-NP
O	620	626	factor	factor	NN	I-NP
O	627	639	independence	independence	NN	I-NP
O	640	642	by	by	IN	B-PP
O	643	650	various	various	JJ	B-NP
O	651	660	oncogenic	oncogenic	JJ	I-NP
O	661	665	PTKs	PTKs	NN	I-NP
O	666	667	(	(	(	O
O	667	670	TEL	TEL	NN	B-NP
O	670	671	/	/	SYM	O
O	671	675	JAK2	JAK2	NN	B-NP
O	675	676	,	,	,	O
O	677	680	TEL	TEL	NN	B-NP
O	680	681	/	/	SYM	I-NP
O	681	685	TRKC	TRKC	NN	I-NP
O	685	686	,	,	,	O
O	687	690	TEL	TEL	NN	B-NP
O	690	691	/	/	SYM	I-NP
O	691	694	ABL	ABL	NN	I-NP
O	694	695	,	,	,	O
O	696	699	BCR	BCR	NN	B-NP
O	699	700	/	/	SYM	I-NP
O	700	703	ABL	ABL	NN	I-NP
O	703	704	,	,	,	O
O	705	709	FLT3	FLT3	NN	B-NP
O	709	710	-	-	HYPH	I-NP
O	710	713	ITD	ITD	NN	I-NP
O	713	714	,	,	,	O
O	715	718	and	and	CC	O
O	719	721	H4	H4	NN	B-NP
O	721	722	/	/	SYM	B-NP
O	722	731	PDGFbetaR	PDGFbetaR	NN	I-NP
O	731	732	)	)	)	O
O	733	737	show	show	VBP	B-VP
O	738	746	abundant	abundant	JJ	B-NP
O	747	757	expression	expression	NN	I-NP
O	758	760	of	of	IN	B-PP
O	761	764	PIM	PIM	NN	B-NP
O	764	765	-	-	HYPH	B-NP
O	765	766	1	1	CD	I-NP
O	767	770	and	and	CC	I-NP
O	771	774	PIM	PIM	NN	I-NP
O	774	775	-	-	HYPH	O
O	775	776	2	2	CD	B-NP
O	776	777	.	.	.	O

O	778	789	Suppression	Suppression	NN	B-NP
O	790	792	of	of	IN	B-PP
O	793	796	PIM	PIM	NN	B-NP
O	796	797	-	-	HYPH	B-NP
O	797	798	1	1	CD	I-NP
O	799	807	activity	activity	NN	I-NP
O	808	811	had	have	VBD	B-VP
O	812	813	a	a	DT	B-NP
O	814	824	negligible	negligible	JJ	I-NP
O	825	831	effect	effect	NN	I-NP
O	832	834	on	on	IN	B-PP
O	835	849	transformation	transformation	NN	B-NP
O	849	850	.	.	.	O

O	851	853	In	In	IN	B-PP
O	854	862	contrast	contrast	NN	B-NP
O	862	863	,	,	,	O
O	864	874	expression	expression	NN	B-NP
O	875	877	of	of	IN	B-PP
O	878	884	kinase	kinase	NN	B-NP
O	884	885	-	-	HYPH	O
O	885	889	dead	dead	JJ	B-NP
O	890	893	PIM	PIM	NN	I-NP
O	893	894	-	-	HYPH	O
O	894	895	2	2	CD	B-NP
O	896	902	mutant	mutant	NN	I-NP
O	903	904	(	(	(	O
O	904	907	PIM	PIM	NN	B-NP
O	907	908	-	-	HYPH	B-NP
O	908	911	2KD	2KD	NN	I-NP
O	911	912	)	)	)	O
O	913	916	led	lead	VBD	B-VP
O	917	919	to	to	TO	B-PP
O	920	921	a	a	DT	B-NP
O	922	927	rapid	rapid	JJ	I-NP
O	928	935	decline	decline	NN	I-NP
O	936	938	of	of	IN	B-PP
O	939	947	survival	survival	NN	B-NP
O	948	950	in	in	IN	B-PP
B-Cell	951	953	Ba	Ba	NN	B-NP
I-Cell	953	954	/	/	SYM	B-NP
I-Cell	954	956	F3	F3	NN	I-NP
I-Cell	957	962	cells	cell	NNS	I-NP
O	963	974	transformed	transform	VBN	B-VP
O	975	977	by	by	IN	B-PP
O	978	982	FLT3	FLT3	NN	B-NP
O	982	983	-	-	HYPH	O
O	983	986	ITD	ITD	NN	B-NP
O	987	990	but	but	CC	B-PP
O	991	994	not	not	RB	B-PP
O	995	997	by	by	IN	I-PP
O	998	1003	other	other	JJ	B-NP
O	1004	1013	oncogenic	oncogenic	JJ	I-NP
O	1014	1018	PTKs	PTKs	NN	I-NP
O	1019	1025	tested	test	VBN	B-VP
O	1025	1026	.	.	.	O

O	1027	1039	Coexpression	Coexpression	NN	B-NP
O	1040	1042	of	of	IN	B-PP
O	1043	1046	PIM	PIM	NN	B-NP
O	1046	1047	-	-	HYPH	B-NP
O	1047	1050	1KD	1KD	NN	I-NP
O	1051	1054	and	and	CC	I-NP
O	1055	1058	PIM	PIM	NN	I-NP
O	1058	1059	-	-	HYPH	B-NP
O	1059	1062	2KD	2KD	NN	I-NP
O	1063	1072	abrogated	abrogate	VBD	B-VP
O	1073	1079	growth	growth	NN	B-NP
O	1080	1086	factor	factor	NN	I-NP
O	1086	1087	-	-	HYPH	B-NP
O	1087	1098	independent	independent	JJ	I-NP
O	1099	1105	growth	growth	NN	I-NP
O	1106	1108	of	of	IN	B-PP
B-Cell	1109	1111	Ba	Ba	NN	B-NP
I-Cell	1111	1112	/	/	SYM	B-NP
I-Cell	1112	1114	F3	F3	NN	I-NP
O	1115	1126	transformed	transform	VBN	B-VP
O	1127	1129	by	by	IN	B-PP
O	1130	1137	several	several	JJ	B-NP
O	1138	1142	PTKs	PTKs	NN	I-NP
O	1142	1143	,	,	,	O
O	1144	1153	including	include	VBG	B-PP
O	1154	1157	BCR	BCR	NN	B-NP
O	1157	1158	/	/	SYM	B-NP
O	1158	1161	ABL	ABL	NN	I-NP
O	1161	1162	.	.	.	O

O	1163	1171	Targeted	Target	VBN	B-VP
O	1172	1176	down	down	RB	B-ADVP
O	1176	1177	-	-	HYPH	B-NP
O	1177	1187	regulation	regulation	NN	I-NP
O	1188	1190	of	of	IN	B-PP
O	1191	1194	PIM	PIM	NN	B-NP
O	1194	1195	-	-	HYPH	O
O	1195	1196	2	2	CD	B-NP
O	1197	1199	by	by	IN	B-PP
O	1200	1203	RNA	RNA	NN	B-NP
O	1204	1216	interference	interference	NN	I-NP
O	1217	1218	(	(	(	O
O	1218	1222	RNAi	RNAi	NN	B-NP
O	1222	1223	)	)	)	O
O	1224	1235	selectively	selectively	RB	B-ADVP
O	1236	1245	abrogated	abrogate	VBD	B-VP
O	1246	1254	survival	survival	NN	B-NP
O	1255	1257	of	of	IN	B-PP
B-Cell	1258	1260	Ba	Ba	NN	B-NP
I-Cell	1260	1261	/	/	SYM	I-NP
I-Cell	1261	1263	F3	F3	NN	I-NP
I-Cell	1264	1269	cells	cell	NNS	I-NP
O	1270	1281	transformed	transform	VBN	B-VP
O	1282	1284	by	by	IN	B-PP
O	1285	1292	various	various	JJ	B-NP
O	1293	1296	Fms	Fm	NNS	I-NP
O	1296	1297	-	-	HYPH	B-NP
O	1297	1301	like	like	JJ	I-NP
O	1302	1310	tyrosine	tyrosine	NN	I-NP
O	1311	1317	kinase	kinase	NN	I-NP
O	1318	1319	3	3	CD	I-NP
O	1320	1321	(	(	(	O
O	1321	1325	FLT3	FLT3	NN	B-NP
O	1325	1326	)	)	)	O
O	1326	1327	-	-	HYPH	O
O	1327	1337	activating	activate	VBG	B-VP
O	1338	1345	mutants	mutant	NNS	B-NP
O	1346	1347	[	[	(	O
O	1347	1355	internal	internal	JJ	B-NP
O	1356	1362	tandem	tandem	JJ	I-NP
O	1363	1374	duplication	duplication	NN	I-NP
O	1375	1376	(	(	(	O
O	1376	1379	ITD	ITD	NN	B-NP
O	1379	1380	)	)	)	O
O	1381	1384	and	and	CC	O
O	1385	1391	kinase	kinase	NN	B-NP
O	1392	1398	domain	domain	NN	I-NP
O	1398	1399	]	]	)	O
O	1400	1403	and	and	CC	O
O	1404	1414	attenuated	attenuate	VBD	B-VP
O	1415	1421	growth	growth	NN	B-NP
O	1422	1424	of	of	IN	B-PP
O	1425	1430	human	human	JJ	B-NP
B-Cell	1431	1435	cell	cell	NN	I-NP
I-Cell	1436	1441	lines	line	NNS	I-NP
O	1442	1452	containing	contain	VBG	B-VP
O	1453	1457	FLT3	FLT3	NN	B-NP
O	1458	1467	mutations	mutation	NNS	I-NP
O	1467	1468	.	.	.	O

O	1469	1482	Interestingly	Interestingly	RB	B-ADVP
O	1482	1483	,	,	,	O
B-Cell	1484	1489	cells	cell	NNS	B-NP
O	1490	1501	transformed	transform	VBN	B-VP
O	1502	1504	by	by	IN	B-PP
O	1505	1509	FLT3	FLT3	NN	B-NP
O	1510	1513	and	and	CC	I-NP
O	1514	1517	BCR	BCR	NN	I-NP
O	1517	1518	/	/	SYM	B-NP
O	1518	1521	ABL	ABL	NN	B-NP
O	1522	1531	mutations	mutation	NNS	I-NP
O	1532	1536	that	that	WDT	B-NP
O	1537	1543	confer	confer	VBP	B-VP
O	1544	1554	resistance	resistance	NN	B-NP
O	1555	1557	to	to	TO	B-PP
O	1558	1563	small	small	JJ	B-NP
O	1563	1564	-	-	HYPH	I-NP
O	1564	1572	molecule	molecule	NN	I-NP
O	1573	1581	tyrosine	tyrosine	NN	I-NP
O	1582	1588	kinase	kinase	NN	I-NP
O	1589	1599	inhibitors	inhibitor	NNS	I-NP
O	1600	1604	were	be	VBD	B-VP
O	1605	1610	still	still	RB	B-ADVP
O	1611	1620	sensitive	sensitive	JJ	B-ADJP
O	1621	1623	to	to	TO	B-PP
O	1624	1633	knockdown	knockdown	NN	B-NP
O	1634	1636	of	of	IN	B-PP
O	1637	1640	PIM	PIM	NN	B-NP
O	1640	1641	-	-	HYPH	B-NP
O	1641	1642	2	2	CD	I-NP
O	1642	1643	,	,	,	O
O	1644	1646	or	or	CC	O
O	1647	1650	PIM	PIM	NN	B-NP
O	1650	1651	-	-	HYPH	B-NP
O	1651	1652	1	1	CD	I-NP
O	1653	1656	and	and	CC	I-NP
O	1657	1660	PIM	PIM	NN	I-NP
O	1660	1661	-	-	HYPH	O
O	1661	1662	2	2	CD	B-NP
O	1663	1665	by	by	IN	B-PP
O	1666	1670	RNAi	RNAi	NNP	B-NP
O	1670	1671	.	.	.	O

O	1672	1675	Our	Our	PRP$	B-NP
O	1676	1688	observations	observation	NNS	I-NP
O	1689	1697	indicate	indicate	VBP	B-VP
O	1698	1702	that	that	IN	B-SBAR
O	1703	1711	combined	combine	VBN	B-NP
O	1712	1724	inactivation	inactivation	NN	I-NP
O	1725	1727	of	of	IN	B-PP
O	1728	1731	PIM	PIM	NN	B-NP
O	1731	1732	-	-	HYPH	B-NP
O	1732	1733	1	1	CD	I-NP
O	1734	1737	and	and	CC	I-NP
O	1738	1741	PIM	PIM	NN	I-NP
O	1741	1742	-	-	HYPH	O
O	1742	1743	2	2	CD	B-NP
O	1744	1754	interferes	interfere	NNS	I-NP
O	1755	1759	with	with	IN	B-PP
O	1760	1769	oncogenic	oncogenic	JJ	B-NP
O	1770	1774	PTKs	PTKs	NN	I-NP
O	1775	1778	and	and	CC	O
O	1779	1786	suggest	suggest	VBP	B-VP
O	1787	1791	that	that	IN	B-SBAR
O	1792	1796	PIMs	PIM	NNS	B-NP
O	1797	1800	are	be	VBP	B-VP
O	1801	1812	alternative	alternative	JJ	B-NP
O	1813	1824	therapeutic	therapeutic	JJ	I-NP
O	1825	1832	targets	target	NNS	I-NP
O	1833	1835	in	in	IN	B-PP
O	1836	1839	PTK	PTK	NN	B-NP
O	1839	1840	-	-	HYPH	B-NP
O	1840	1848	mediated	mediate	VBN	I-NP
B-Cancer	1849	1857	leukemia	leukemia	NN	I-NP
O	1857	1858	.	.	.	O

O	1859	1868	Targeting	Target	VBG	B-VP
O	1869	1872	the	the	DT	B-NP
O	1873	1876	PIM	PIM	NN	I-NP
O	1877	1883	kinase	kinase	NN	I-NP
O	1884	1890	family	family	NN	I-NP
O	1891	1896	could	could	MD	B-VP
O	1897	1904	provide	provide	VB	I-VP
O	1905	1906	a	a	DT	B-NP
O	1907	1910	new	new	JJ	I-NP
O	1911	1917	avenue	avenue	NN	I-NP
O	1918	1920	to	to	TO	B-VP
O	1921	1929	overcome	overcome	VB	I-VP
O	1930	1940	resistance	resistance	NN	B-NP
O	1941	1948	against	against	IN	B-PP
O	1949	1954	small	small	JJ	B-NP
O	1954	1955	-	-	HYPH	I-NP
O	1955	1963	molecule	molecule	NN	I-NP
O	1964	1972	tyrosine	tyrosine	NN	I-NP
O	1973	1979	kinase	kinase	NN	I-NP
O	1980	1990	inhibitors	inhibitor	NNS	I-NP
O	1990	1991	.	.	.	O

